Modular Medical shares surge 13.45% after-hours after validating Pivot controller line for human-use production ahead of Q1 2026 launch.

Modular Medical surged 13.45% in after-hours trading following the announcement that it successfully validated its Pivot controller manufacturing line for human-use production, a critical step toward its Q1 2026 commercial launch. The company emphasized this milestone as evidence of scalable production capabilities in the patch pump market, with CEO Jeb Besser highlighting it as a key differentiator. Recent developments, including completion of a clinical study for its MODD1 pump, a $4.4 million warrant raise, and the appointment of David Bosshard to lead international expansion, further underscore strategic progress. Despite financial challenges and the absence of FDA clearance, the validation signals readiness for high-volume production of the Pivot, a tubeless insulin delivery system targeting a $3 billion market. The second news item, referencing Yahoo Finance’s general stock performance data, was deemed irrelevant.